Myriad Genetics

SALT LAKE CITY, May 26, 2026 Myriad Genetics announced the launch of Prolaris® + AI, the first prostate cancer...

SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

Dateline — SALT LAKE CITY, November 11, 2025:Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostic testing...